ProjectRD.06.SPR.118161 – A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of…
Basic data
Acronym:
RD.06.SPR.118161
Title:
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis
Duration:
08/02/2021 to 01/02/2022
Abstract / short description:
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with
Moderate-to-Severe Atopic Dermatitis
Moderate-to-Severe Atopic Dermatitis
Keywords:
atopic dermatitis
Atopische Dermatitis
Involved staff
Managers
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Contact persons
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
CRC-TR 156 - The Skin as a Sensor and Effector Organ Orchestrating Local and Systemic Immune Responses
Collaborative research centers and transregios
Collaborative research centers and transregios
Cluster of Excellence: Image-Guided and Functionally Instructed Tumor Therapies (iFIT)
Centers or interfaculty scientific institutions
Centers or interfaculty scientific institutions
Other staff
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine
Faculty of Medicine
Funders
La Tour-de-Peilz, Switzerland